Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial

BACKGROUND: Angiogenesis and activation of the epidermal growth factor (EGFR) pathway play an essential role in tumor proliferation and metastasis. Targeting angiogenesis or EGFR alone does not yield adequate tumor control in most solid tumors. Overcoming intrinsic and/or acquired resistance may nee...

Descripción completa

Detalles Bibliográficos
Autores principales: Subbiah, Vivek, Dumbrava, Ecaterina Ileana, Jiang, Yunfang, Thein, Kyaw Z., Naing, Aung, Hong, David S., Fu, Siqing, Piha-Paul, Sarina A., Tsimberidou, Apostolia M., Janku, Filip, Meric-Bernstam, Funda, Kurzrock, Razelle, Falchook, Gerald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7171918/
https://www.ncbi.nlm.nih.gov/pubmed/32337094
http://dx.doi.org/10.1186/s40164-020-00159-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7171918/
https://www.ncbi.nlm.nih.gov/pubmed/32337094
http://dx.doi.org/10.1186/s40164-020-00159-1

Ejemplares similares